AustralianSuper Pty Ltd Sells 2,791 Shares of Thermo Fisher Scientific Inc. $TMO

AustralianSuper Pty Ltd trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,790 shares of the medical research company’s stock after selling 2,791 shares during the quarter. AustralianSuper Pty Ltd’s holdings in Thermo Fisher Scientific were worth $3,564,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of TMO. CBIZ Investment Advisory Services LLC boosted its holdings in shares of Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC purchased a new position in Thermo Fisher Scientific in the first quarter valued at about $30,000. Keystone Global Partners LLC bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $31,000. DiNuzzo Private Wealth Inc. lifted its stake in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC increased its position in Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after buying an additional 45 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,666 shares of company stock worth $13,990,971 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $564.49 on Tuesday. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $213.16 billion, a PE ratio of 32.61, a price-to-earnings-growth ratio of 3.35 and a beta of 0.77. The firm’s 50 day simple moving average is $505.57 and its 200 day simple moving average is $454.34.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analyst estimates of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the business earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on TMO. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Leerink Partners increased their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. TD Cowen upped their price target on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Citigroup raised their price objective on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Finally, HSBC reissued a “hold” rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $595.75.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.